Famotidine detailed information

Famotidine (INN) is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of  peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by J&J/Merck under the trade names Pepcidine and Pepcid.

Clinical use
Main article: H2-receptor antagonist

Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States, preparations of 10 mg and 20 mg tablets, sometimes in combination with a more traditional antacid, are available OTC. Larger doses still require a prescription.

Famotidine is given to surgery patients before operations to prevent post-operation nausea and to reduce the risk of aspiration pneumonitis.

History and development
Famotidine was developed by Merck & Co. and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole-ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 30 times more active than cimetidine.

It was first marketed in 1985. Pepcid RPD orally-disintegrating tablets (that are not swallowed) was released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.). In the United States, a product called Pepcid Complete is available that combines famotidine with an antacid in a chewable tablet to ameliorate the relatively slow onset of effects. In the UK, this product is known as Pepcidtwo.

Famotidina Famotidine ファモチジン Famotydyna ฟาโมติดีน Famotidin